An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
Conflict of Interest Disclosures: Dr Collier reported grants from the Massachusetts Consortium on Pathogen Readiness (MassCPR) during the conduct of the study. Dr Barouch reported grants from the Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, Bill & Melinda Gates Foundation, Henry M. Jackson Foundation, MassCPR, National Cancer Institute, National Institute of Allergy and Infectious Diseases (NIAID), Ragon Institute, South African Medical Research Council, Walter Reed Army Institute of Research, Alkermes, CureVac, Gilead, Gritstone, GSK, Hookipa, Intima, Janssen, Legend, Leyden Labs, Musk Foundation, Novavax, Pfizer, Pharm-Olam, Sanofi, and Zentalis; equity in Celsion/Imunon; and consulting fees from Avidea, Celsion/Imunon, Laronde, Meissa, SQZ, and Sterne Kessler; and is the founder of and has equity in Vector Sciences outside the submitted work. No other disclosures were reported.
Figures
Figure.. Serum Mpox Antibody Responses After 2-Dose…
Figure.. Serum Mpox Antibody Responses After 2-Dose and 1-Dose Modified Vaccinia Ankara–Bavarian Nordic (MVA-BN) Vaccination…
Figure.. Serum Mpox Antibody Responses After 2-Dose and 1-Dose Modified Vaccinia Ankara–Bavarian Nordic (MVA-BN) Vaccination Over Time
Mpox-specific enzyme-linked immunosorbent assay (ELISA) (A and B) and 50% neutralizing antibody (NAb) titers (NT50) (C). Peak immunity was defined as 3 weeks after final vaccination. Titers less than 30 are considered negative. Horizontal red bars reflect median values. Numbers above the antigen data points reflect median titers.
Del Rio C, Malani PN. Update on the monkeypox outbreak. JAMA. 2022;328(10):921-922. doi:10.1001/jama.2022.14857
-
DOI
-
PubMed
Deputy NP, Deckert J, Chard AN, et al. . Vaccine effectiveness of JYNNEOS against mpox disease in the United States. N Engl J Med. 2023;388(26):2434-2443. doi:10.1056/NEJMoa2215201
-
DOI
-
PMC
-
PubMed
Jacob-Dolan C, Ty D, Hope D, et al. . Comparison of the immunogenicity and protective efficacy of ACAM2000, MVA, and vectored subunit vaccines for mpox in rhesus macaques. Sci Transl Med. 2024;16(740):eadl4317. doi:10.1126/scitranslmed.adl4317
-
DOI
-
PubMed